Fujirebio Holdings’ portfolio of biomarkers and diagnostic tools for Parkinson’s disease now includes tailor-made antibodies against the protein alpha-synuclein with the company’s acquisition of ADx NeuroSciences. The $40 million acquisition is expected to be complete in July, pending the satisfaction of customary closing conditions.

PreciseDx’s artificial intelligence (AI) platform shows an ability to accurately diagnose Parkinson’s disease in people before they develop severely evident symptoms, according to a new study. Conducted in collaboration with The Michael J. Fox Foundation (MJFF), the study’s findings support the platform’s potential to aid in diagnosing Parkinson’s and allowing patients to begin…

A positron emission tomography (PET) tracer for the alpha-synuclein protein, whose damaging clumps mark Parkinson’s, captured its toxic aggregates in a living brain for a first time — instead of in post-mortem tissue as is done to date, scientists reported. The tracer, called ACI-12589, is a diagnostic tool designed to…

A protein modification that disrupts how cells dispose of “worn-out” proteins may promote the spread of the alpha-synuclein toxic clumps known to cause Parkinson’s disease, a study reported. “We think our findings about this apparent disease-driving process are important for developing compounds that can specifically inhibit the process of…

Parkinson’s patients have a subpopulation of astrocytes — brain cells that support neuronal function and health — that produce a vitamin D-activating enzyme called CYP27B1 and are involved in clearing the toxic alpha-synuclein clumps that form in the disease. The small study compared deceased Parkinson’s…

Winners of the 2022 edition of the $3 million Cure One, Cure Many Award for the early diagnosis of Lewy body dementia (LBD) have been announced by its promoter, the American Brain Foundation. They are the Mayo Clinic’s Owen A. Ross, PhD, Pamela J. McLean, PhD, and…

Athira Pharma has dosed the first patient in its Phase 2 clinical trial evaluating ATH-1017 as a treatment for Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) — forms of more severe cognitive impairment in Parkinson’s disease. The trial (NCT04831281), known as SHAPE, is still…

A new molecule — a peptide tweaked by scientists in the laboratory — has the potential to prevent the misfolding and toxic aggregation, or clumping, of misfolded alpha-synuclein protein, a hallmark of Parkinson’s disease, a study shows. This study, supported by funds from Alzheimer’s Research U.K., paves the…

According to a 2013 article in The New York Times, the average American knows about 600 people. Since the debut of “Life, Lemons, and Lemonade” over two years ago, I have met many doctors, community educators, foundation directors, researchers, and people with Parkinson’s disease. Between fundraisers, Zoom support…

ABBV-0805, AbbVie’s experimental antibody-based therapy for Parkinson’s disease, selectively binds to toxic clumps of the alpha-synuclein protein — a hallmark of the disease — preventing their spread and prolonging survival in mouse models of Parkinson’s, a study shows. Also, the investigational antibody was found to bind to harmful…